RU
Address
220006, Minsk, Leningradskaya Str. 6, office 2
Tel.: +375 17 363-88-92
E-mail: medjournal@bsmu.by
  • Главная
  • Выпуски
  • 2026 №4
  • Поиск биомаркеров немелкоклеточного рака легкого: показатели воспаления и клеточной адгезии для диагностики и прогнозирования возврата заболевания

Поиск биомаркеров немелкоклеточного рака легкого: показатели воспаления и клеточной адгезии для диагностики и прогнозирования возврата заболевания

А. Д. Таганович, Н. Н. Ковганко УО «Белорусский государственный медицинский университет»
DOI:  https://doi.org/10.51922/1818-426X.2026.4.46
2026 №4 | Обзоры
Аннотация
Список литературы
Скачать полнотекстовую статью
Цель. Проанализировать данные об использовании биомаркеров воспалительного ответа и клеточной адгезии в диагностике и прогнозировании возврата заболевания при немелкоклеточном раке легкого.
Результаты. В обзоре анализируются данные об использовании клеток крови, продуцируемых ими цитокинов CXCL5, CXCL8, рецепторов для них CXCR1, CXCR2, рецептора клеточной адгезии (CD44v6) и С-реактивного белка в качестве диагностических и прогностических биомаркеров возврата заболевания при немелкоклеточном раке легкого. Показаны перспективность этого направления и имеющиеся недостатки.
Выводы. Для улучшения диагностики и прогнозирования безрецидивной выживаемости немелкоклеточного рака легкого перспективным является комплексное определение цитокинов, их рецепторов – участников воспалительного ответа организма на развивающуюся опухоль, и рецептора CD44v6, отобранных на основе множественного регрессионного анализа.
Ключевые слова:
немелкоклеточный рак легкого, клеточная адгезия, С-реактивный белок.
Search for biomarkers of non-small cell lung cancer: indicators of inflammation and cell adhesion for diagnosis and prediction of disease recurrence

Objective. To analyze data on the use of inflammatory response and cell adhesion biomarkers in the diagnosis and prognosis of disease recurrence in non-small cell lung cancer.
Results. This review analyzes data on the use of blood cells, the cytokines (CXCL5 and CXCL8), their receptors (CXCR1 and CXCR2), the cell adhesion receptor (CD44v6), and C-reactive protein as diagnostic and prognostic biomarkers of disease recurrence in non-small cell lung cancer. The potential of this approach and its limitations are demonstrated.
Conclusions. To improve the diagnosis and prognosis of relapse-free survival in non-small cell lung cancer, a comprehensive determination of cytokines, their receptors – participants in the body's inflammatory response to a developing tumor, and the CD44v6 receptor, selected on the basis of multiple regression analysis, is promising.

Keywords
non-small cell lung cancer, cell adhesion, C-reactive protein
    • Grivennikov, S. I., Greten F. R., Karin M. Immunity, inflammation, and cancer // Cell. – 2010. – Vol. 140, № 6. – P. 883–99. – doi: 10.1016/j.cell.2010.01.025.
    • The Role of Tumor-Infiltrating Lymphocytes in Development, Progression, and Prognosis of Non-Small Cell Lung Cancer / R. M. Bremnes, L. T. Busund, T. L. Kilvær [et al.] // Thorac Oncol. – 2016. – № 11(6). – Р. 789–800. – doi: 10.1016/j.jtho.2016.01.015. 
    • Cancer-related inflammation / A. Mantovani, P. Allavena, A. Sica [et al.] // Nature. – 2008. – Vol. 454, № 7203. – P. 436–44. – doi: 10.1038/nature07205. 
    • An updated review on the role of the CXCL8-CXCR1/2 axis in the progression and metastasis of breast cancer / A. Mishra, K. H. Suman, N. Nair [et al.] // Molecular Biology Reports. – 2021. – Vol. 48, № 9. – P. 6551–6561. – doi: 10.1007/s11033-021-06648-8.
    • Elevated serum interleukin-8 is associated with enhanced intratumor neutrophils and reduced clinical benefit of immunecheckpoint inhibitors / K. A. Schalper, M. Carleton, M. Zhou [et al.] // Nature Medicine. – 2020. – Vol. 26, № 5. – P. 688–692. – doi: 10.1038/s41591-020-0856-x.
    • Ha, H. Role of the CXCL8-CXCR1/2 Axis in Cancer and Inflammatory Diseases / H. Ha, B. Debnath, N. Neamati // Theranostics. – 2017. – Vol. 7, № 6. – Р. 1543–1588. – doi: 10.7150/thno.15625.
    • Serum chemokine CXCL8 is a better biomarker for diagnosis and prediction of pancreatic cancer than its specific receptor CXCR2, C-reactive protein, and classic tumor markers CA 19–9 and CEA / A. Litman-Zawadska, M. Łukaszewicz-Zając, M. Gryko [et al.] // Polish archives of internal medicine. – 2018. – Vol. 128, № 9. – P. 524–531. – doi: 10.7150/thno.15625.
    • Interleukin-8 serum levels in patients with benign prostatic hyperplasia and prostate cancer / R. W. Veltri, M. C. Miller, G. Zhao [et al.] // Urology. – 1999. – Vol. 53, № 1. – P. 139–147. – doi: 10.1016/s0090-4295(98)00455-5.
    • Validation and clinicopathologic associations of a urinebased bladder cancer biomarker signature / G. Zhang, E. Gomes-Giacoia, Y. Dai [et al.] // Diagnostic Pathology. – 2014. – Vol. 9. – P. 200–209. – doi: 10.1186/s13000-014-0200-1.
    • Comparison between clinical significance of serum CXCL-8 and classical tumor markers in oesophageal cancer (OC) patients / M. Łukaszewicz-Zając, S. Pączek, P. Muszyński [et al.] // Clinical and Experimental Medicine. – 2019. – Vol. 19, № 2. – P. 191–199. – doi: 10.1007/s10238-019-00548-9. 
    • Expression of CXCL8 and its relationship with prognosis in patients with non-small cell lung cancer / X. Ma, X. Zhu, M. Zou [et al.] // American Journal of Cancer Research. – 2024. – Vol. 14, № 6. – P. 2934–2945. – doi: 10.62347/LJDQ3897.
    • DACH1 antagonizes CXCL8 to repress tumorigenesis of lung adenocarcinoma and improve prognosis / Q. Liu, A. Li, S. Yu [et al.] // Journal of Hematology and Oncology. – 2018. – Vol. 11, № 1. – 53. – doi: 10.1186/s13045-018-0597-1. 
    • Sepuru, K. M. Solution structure of CXCL5-a novel chemokine and adipokine implicated in inflammation and obesity / K. M. Sepuru, K. M. Poluri, K. Rajarathnam // PLoS One. – 2014. – Vol. 9, № 4. – Р. e93228. – doi: 10.1371/journal.pone.0093228.
    • CXCL5 induces tumor angiogenesis via enhancing the expression of FOXD1 mediated by the AKT/NF-κB pathway in colorectal cancer / C. Chen, Z. Q. Xu, Y. P. Zong [et al.] // Cell Death and Disease. – 2019. – Vol. 10, № 3. – Р. 178. – doi: 10.1038/s41419-019-1431-6.
    • DACH1 inhibits lung adenocarcinoma invasion and tumor growth by repressing CXCL5 signaling / N. Han, X. Yuan, H. Wu [et al.] // Oncotarget. – 2015. – Vol. 6, № 8. – Р. 877–888. – doi:10.18632/oncotarget.3463. 
    • Prognostic value of hyaluronan expression in non-small-cell lung cancer: Increased stromal expression indicates unfavorable outcome in patients with adenocarcinoma / R. Pirinen, R. Tammi, M. Tammi [et al.] // International Journal of Cancer. – 2001. – Vol. 95, № 1. – P. 12–17. – doi: 10.1002/1097-0215(20010120)95:1<12::aid-ijc1002>3.0.co;2-e.
    • Diagnostic value of circulating CXC chemokines in nonsmall cell lung cancer / A. Sparks, I. Jaunalksne, I. Spaka [et al.] // Anticancer Research. – 2015. – Vol. 35, № 12. – P. 6979–6983. 
    • CXCL5 as a potential novel prognostic factor in earlystage non-small cell lung cancer: results of a study of expression levels of 23 genes / O. Kowalczuk, T. Burzykowski, W. Niklinska [et al.] // Tumour Biology. – 2014. – Vol. 35, № 5. – Р. 4619–4628. – doi: 10.1007/s13277-014-1605-x.
    • Identification of CXCL5 expression as a predictive biomarker associated with response and prognosis of immunotherapy in patients with non-small cell lung cancer / J. Deng, X. Ma, Y. Ni [et al.] // Cancer Medicine. – 2022. – Vol. 11, № 8. – P. 1787–1795. – doi: 10.1002/cam4.4567.
    • Differential activation and regulation of CXCR1 and CXCR2 by CXCL8 monomer and dimer / M. Nassar, S. K. Raghuwanshi, D. J. Grant [et al.] // Journal of Immunology. – 2009. – Vol. 183, № 5. – P. 3425–3432. – doi: 10.4049/jimmunol.0900305.
    • The expression and prognostic impact of CXC-chemokines in stage II and III colorectal cancer epithelial and stromal tissue / O. Oladipo, S. Conlon, A. O’Grady [et al.] // British journal of cancer. – 2011. – Vol. 104, № 3. – P. 480–487. – doi:10.1038/sj.bjc.6606055.
    • Expression characteristic of CXCR1 in different breast tissues and the relevance between its expression and efficacy of neo-adjuvant chemotherapy in breast cancer / M. Xue, J. Liu, L. Su [et al.] // Oncotarget. – 2017. – Vol. 8, № 30. – P. 48930–48937. – doi: 10.18632/oncotarget.16893. 
    • Chu, H. C-X-C motif chemokine receptor type 2 correlates with higher disease stages and predicts worse prognosis, and its downregulation enhances chemotherapy sensitivity in triple-negative breast cancer / H. Chu, W. Li, H. Li // Translational Cancer Research. – 2020. – Vol. 9, № 2. – P. 840–848. – doi:10.21037/tcr.2019.12.38.
    • CXCR2 expression in tumor cells is a poor prognostic factor and promotes invasion and metastasis in lung adenocarcinoma / P. Saintigny, E. Massarelli, S. Lin [et al.] // Cancer research. – 2013. – Vol. 73, № 2. – P. 571–582. – doi: 10.1158/0008-5472.CAN-12-0263.
    • Loss of β-arrestin-2 and activation of CXCR2 correlate with lymph node metastasis in non-small cell lung cancer / L. Cong, Z. Y. Qiu, Y. Zhao [et al.] // Journal of cancer. – 2017. – Vol. 8, № 14. – P. 2785–2792. – doi: 10.7150/jca.19631.
    • Association of chemokine and chemokine receptor expression with the invasion and metastasis of lung carcinoma / Y. Lui, B. Wu, H. Geng [et al.] // Oncology Letters. – 2015. – Vol. 10, № 3. – Р. 1315–1322. – doi: 10.3892/ol.2015.3402.
    • Interleukin-8/CXCL8 is a growth factor for human lung cancer cells / Y. M. Zhu, S. Webster, D. Flower [et al.] // British Journal of Cancer. – 2004. – Vol. 91, № 11. – P. 1970–1976. – doi: 10.1038/sj.bjc.6602227.
    • Chemokine receptor expression in tumour islets and stroma in non-small cell lung cancer / C. M. Ohri, A. Shikotra, R. H. Green [et al.] // BMC Cancer. – 2010. – Vol. 10. – Р. 172. – doi: 10.1186/1471-2407-10-172.
    • Agassandian, M. C-reactive protein and lung diseases / M. Agassandian, G. V. Shurin Ma Y., M. R. Shurin // International Journal of Biochemistry and Cell Biology. – 2014. – Vol. 53. – P. 77–88. – doi:10.1016/j.biocel.2014.05.016.
    • Role of C reactive protein in non-small cell lung cancer staging / J. A. Torrecilla, S. Scrimini, J. Sauleda [et al.] // European Respiratory Journal. – 2011. – Vol. 38, suppl. 55. – P. 2806. – doi:10.1183/13993003/erj.38.Suppl_55.p2806. 
    • Aref, H. CRP evaluation in non-small cell lung cancer / H. Aref, S. Refaat // Egyptian Journal of Chest Diseases and Tuberculosis. – 2014. – Vol.63, № 3. – P. 717–772. – doi: 10.1016/j.ejcdt.2014.02.003.
    • Tumor-infiltrating platelets promote the growth of lung adenocarcinoma / X. Li, M. Li, Z. Hu [et al.] // Translational Oncology. – 2024. – Vol. 39. – Р. 101813. – doi: 10.1016/j.tranon. 2023.101813.
    • The inflammatory burden index is a superior systemic inflammation biomarker for the prognosis of non-small cell lung cancer / H. Xie, G. Ruan, L. Wei [et al.] // Journal of Cachexia Sarcopenia and Muscle. – 2023. – Vol. 14, № 2. – P. 869–878. – doi: 10.1002/jcsm.13199.
    • The Role of Macrophages in Cancer Development and Therapy / E. Cendrowicz, Z. Sas, E. Bremer, T. P. Rygiel // Cancers (Basel). – 2021. – Vol. 13, № 8. – Р. 1946. – doi: 10.3390/cancers13081946.
    • Non-small cell lung cancer cells induce monocytes to increase expression of angiogenic activity / E. S. White, S. R. Strom, N. L. Wys, D. A. Arenberg // Journal of Immunology – 2001. – Vol. 166, № 12. – P. 7549–7555. – doi: 10.4049/ jimmunol.166.12.7549. 
    • Zhou, J. Role of tumor associated neutrophils in lung cancer (Review) / J. Zhou, H. Liu, S. Jiang, W. Wang // Oncology Letters. – 2023. – Vol. 25, № 1. – Р. 2. – doi: 10.3892/ol.2022. 13588.
    • Schlesinger, M. Role of platelets and platelet receptors in cancer metastasis / M. Schlesinger // Journal of Hematology and Oncology. – 2018. – Vol. 11, № 1. – Р. 125. – doi: 10.1186/s13045-018-0669-2.
    • Lymphocyte percentage as a valuable predictor of prognosis in lung cancer / H. Huang, L. Li, W. Luo [et al.] // Journal of Cellular and Molecular Medicine. – 2022. – Vol. 26, № 7. – P. 1918–1931. – doi: 10.1111/jcmm.17214.
    • Elevations of monocyte and neutrophils, and higher levels of granulocyte colony-stimulating factor in peripheral blood in lung cancer patients / W. Yin, J. Lu, Y. Yao [et al.] // Thoracic Cancer. – 2021. – Vol. 12, № 20. – P. 2680–2690. – doi: 10.1111/1759-7714.14103.
    • Platelet count predicts prognosis in operable non-small cell lung cancer / D. Yu, B. Liu, L. Zhang, K. Du // Experimental and Therapeutic Medicine. – 2013. – Vol. 5, № 5. – P. 1351–1354. – doi: 10.3892/etm.2013.1003.
    • Elevated platelet count is a strong predictor of poor prognosis in stage I non-small cell lung cancer patients / Y. Ji, L. Sheng, X. Du [et al.] // Platelets. – 2015. – Vol. 26, № 2. – P. 138–142. – doi: 10.3109/09537104.2014.888547.
    • Preresection serum C-reactive protein measurement and survival among patients with resectable non–small cell lung cancer / M. Alifano, P. E. Falcoz, V. Seegers [et al.] // Journal of Thoracic and Cardiovascular Surgery. – 2011. – Vol. 142, № 5. – P. 1161–1167. – doi: 10.1016/j.jtcvs.2011.07.021.
    • Miao, S. The Multifaceted Role of Neutrophils in NSCLC in the Era of Immune Checkpoint Inhibitors / S. Miao, B. L. Rodriguez, D. L. Gibbons // Cancers (Basel). – 2024. – Vol. 16, № 14. – Р. 2507. – doi: 10.3390/cancers16142507.
    • Prognostic performance of inflammation-based prognostic indices in primary operable non-small cell lung cancer / D. J. Pinato, R. J. Shiner, M. J. Seckl [et al.] // British Journal of Cancer. – 2014. – Vol. 110, № 8. – P. 1930–1935. – doi: 10.1038/bjc. 2014.145.
    • Masoud, G. HIF-1α pathway: role, regulation and intervention for cancer therapy / G. Masoud, L. Wei // Acta Pharmacologica Sinica. – 2015. – Vol. 5, № 5. – P. 378–389. – doi: 10.1016/j.apsb.2015.05.007.
    • Heider, K. H. CD44v6: a target for antibody-based cancer therapy / K. H. Heider // Cancer Immunology and Immunotherapy. – 2004. – Vol. 53, № 7. – P. 567–579. – doi: 10.1007/s00262-003-0494-4.
    • Expression of CD44 abnormal transcripts in human gastric carcinomas / H. Yokozaki, R. Ito, H. Nakayama [et al.] // Cancer Letters. – 1994. – Vol. 83, № 1-2. – P. 229–234. – doi: 10.1016/0304-3835(94)90324-7. 
    • The biology and role of CD44 in cancer progression: therapeutic implications / C. Chen, S. Zhao, A. Karnad, J. W. Freeman // Journal of Hematology and Oncology. – 2018. – Vol. 11, № 1. – Р. 64. – doi: 10.1186/s13045-018-0605-5.
    • CD44v/CD44s expression patterns are associated with the survival of pancreatic carcinoma patients / Z. Li, K. Chen, P. Jiang [at al.] // Diagnostic Pathology. – 2014. – Vol. 9. – Р. 79. – doi: 10.1186/1746-1596-9-79.
    • CD44v6 acts as a directional responding factor in the process of transcoelomic metastasis from gastric carcinoma to Krukenberg tumor / Z. Zhou, C. Li, Z. Wang [et al.] // Expert Review of Molecular Diagnostics. – 2023. – Vol. 23, № 7. – P. 583–588. – doi: 10.1080/14737159.2023.2223981.
    • The expression of the CD44 variant exon 6 is associated with lymph node metastasis in non-small cell lung cancer / T. Miyoshi, K. Kondo, N. Hino [et al.] // Clinical cancer research. – 1997. – Vol. 8. – P. 1289–1297. 
    • Expression of CD44s and CD44v6 in lung cancer and their correlation with prognostic factors / A. M. Afify, S. Tate, B. Durbin-Johnson [et al.] // International Journal of BiologicalMarkers. – 2011. – Vol. 26, № 1. – P. 50–57. – doi: 10.5301/jbm.2011.6291.
    • Dynamics of Serum Tumor Markers Can Serve as a Prognostic Biomarker for Chinese Advanced Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors / Z. Zhang, F. Yuan, R. Chen [et al.] // Frontiers in Immunology. – 2020. – Vol. 11. – Р. 1173. – doi: 10.3389/fimmu.2020.01173.
    • Prognostic Value of Serum Tumor Markers in Patients with Stage III NSCLC Treated With Chemoradiotherapy / T. Tokito, K. Azuma, K. Yamada [et al.] // In Vivo. – 2019. – Vol. 33, № 3. – P. 889–895. – doi: 10.21873/invivo.11555.
    • Postoperative CYFRA 21-1 and CEA as prognostic factors in patients with stage I pulmonary adenocarcinoma / Y. He, Y. Cui, D. Chang, T. Wang // Oncotarget. – 2017. – Vol. 84, № 2. – P. 73115–73122. – doi: 10.18632/oncotarget.17611.
    • The Evaluation of Serum Biomarkers for Non-small Cell Lung Cancer (NSCLC) Diagnosis / R. Fang, Y. Zhu, V. S. Khadka [et al] // Frontiers in Physiology. – 2018. – Vol. 9. – Р. 1710. – doi: 10.3389/fphys.2018.01710.
    • Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? / M. Plebani, D. Basso, F. Navaglia [et al.] // British Journal of Cancer. – 1995. – Vol. 72, № 1. – P. 170–173. – doi: 10.1038/bjc.1995.296.
    • Wang, W. What’s the difference between lung adenocarcinoma and lung squamous cell carcinoma? Evidence from a retrospective analysis in a cohort of Chinese patients / W. Wang, H. Liu, G. Li // Frontiers in Endocrinology (Lausanne). – 2022. – Vol. 13. – Р. 947443. – doi: 10.3389/fendo.2022.947443. 
    • Kumar, S., Logistic regression in cancer research: A narrative review of the concept, analysis, and interpretation / S. Kumar, V. Gota // Cancer Research, Statistics and Treatment. – 2023. – Vol. 6, № 4. – P. 573–578. – doi: 10.4103/crst.crst_293_23. 
    • Early Lung Cancer Prediction using Correlation and Regression / K. Sivanagireddy, S. Yerram, S. S. N. Kowsalya [et al.] // International Conference on Computer, Power and Communications (ICCPC). – 2022. – P. 24–28. – doi:10.1109/ICCPC55978.2022.10072059.